TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37550958

Group type: EXPERIMENTAL
Intervention: PrecivityAD blood test (mass spectrometry test measuring amyloid beta and ApoE blood biomarkers)
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: PrecivityAD blood test
Number of subjects: 366
Study: 37551153

Group type: EXPERIMENTAL
Intervention: Intra-operative mean α power
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Intra-operative maximum α power
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Pre-operative cognitive z scores
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 220
Study: 37551324

Group type: EXPERIMENTAL
Intervention: Active surveillance (weekly)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Immunoglobulin G positivity
Number of subjects: 500
Study: 37551412

Group type: EXPERIMENTAL
Intervention: 150 min/wk of moderate-intensity aerobic, resistance, or combination exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-exercising control
Number of subjects: 0
Study: 37551512

Group type: EXPERIMENTAL
Intervention: Fortified human milk diet (intervention group)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard unfortified diet (control group)
Number of subjects: 150
Study: 37551532

Group type: EXPERIMENTAL
Intervention: Drug-Eluting Balloon (DEB) angioplasty (SEQUENT PLEASE)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Drug-Eluting Stent (DES) (Promus Premier and Promus Elite)
Number of subjects: 290
Study: 37551542

Group type: EXPERIMENTAL
Intervention: AID (MiniMed™ 780G)
Number of subjects: 75

Group type: COMPARATOR
Intervention: MDI+isCGM (Control)
Number of subjects: 75
Study: 37551550

Group type: EXPERIMENTAL
Intervention: Labisia pumila standardized extract (SKF7®) 750 mg
Number of subjects: 133
Study: 37551609

Group type: EXPERIMENTAL
Intervention: Cariprazine 1.5 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cariprazine 3 mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37551762

Group type: EXPERIMENTAL
Intervention: Initial weight change (WC) during the initial 2, 4, and 8 weeks
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Self-weighing and adherence to the expected WC trajectory
Number of subjects: 452
Study: 37551841

Group type: COMPARATOR
Intervention: Fibrin-based haemostatic agents (FBHAs)
Number of subjects: 2945
Study: 37552083

Group type: EXPERIMENTAL
Intervention: Local clinical site diagnoses
Number of subjects: 918

Group type: EXPERIMENTAL
Intervention: Central, adjudicated review diagnoses
Number of subjects: 918

Group type: EXPERIMENTAL
Intervention: Therapies reported
Number of subjects: 918

Group type: COMPARATOR
Intervention: True discordance in diagnosis
Number of subjects: 918

Group type: COMPARATOR
Intervention: Inappropriate therapy
Number of subjects: 918
Study: 37552281

Group type: EXPERIMENTAL
Intervention: Osia 2 System
Number of subjects: 20
Study: 37552303

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/d (n=150)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo (n=150)
Number of subjects: 300
Study: 37552330

Group type: EXPERIMENTAL
Intervention: Vitamin K4 (1 mg) for 24 weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo for 24 weeks
Number of subjects: 90
Study: 37552367

Group type: EXPERIMENTAL
Intervention: SGM-101 (carcinoembryonic antigen specific fluorescent tracer)
Number of subjects: 13
Study: 37552407

Group type: EXPERIMENTAL
Intervention: Telmisartan (10-80 mg daily)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Enalapril (5-40 mg daily)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 107

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 107
Study: 37552872

Group type: EXPERIMENTAL
Intervention: EVAD tool for evaluating and classifying the severity of adverse events
Number of subjects: 0
Study: 37552988

Group type: EXPERIMENTAL
Intervention: High-dimensional mass cytometry analysis of peripheral blood immune composition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supervised and unsupervised analysis methods to study cell-type proportions
Number of subjects: 0
Study: 37553227

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine for 5 days
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo for 5 days
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine and Placebo
Number of subjects: 198
Study: 37553238

Group type: EXPERIMENTAL
Intervention: Control charts for monitoring surgical outcomes provided to intervention hospitals
Number of subjects: 155362
Study: 37553297

Group type: EXPERIMENTAL
Intervention: Palbociclib (50 mg/m2) in combination with standard four-drug re-induction chemotherapy
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard four-drug re-induction chemotherapy
Number of subjects: 12
Study: 37553338

Group type: EXPERIMENTAL
Intervention: Ad5-nCoV
Number of subjects: 200

Group type: COMPARATOR
Intervention: inactivated SARS-CoV-2 vaccine
Number of subjects: 200
Study: 37553467

Group type: EXPERIMENTAL
Intervention: PLX-R18 (1 million cells/kg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: PLX-R18 (2 million cells/kg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: PLX-R18 (4 million cells/kg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: PLX-R18
Number of subjects: 21
Study: 37553488

Group type: EXPERIMENTAL
Intervention: MRI-guided focused ultrasound (MRgFUS) treatment
Number of subjects: 99
Study: 37553560

Group type: EXPERIMENTAL
Intervention: Multi-component SDM implementation program
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Qualitative process evaluation
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Qualitative data analysis
Number of subjects: 126
Study: 37553637

Group type: EXPERIMENTAL
Intervention: Wilderness program (8-day expedition including backpacking, sea kayaking, gorge climbing, camping, bush-craft skills, and mindfulness practices, followed by a 4-day basecamp after 3 months)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Holiday program (8-day holiday program at a Spa-hotel followed by a 4-day holiday program at the same hotel after 3 months)
Number of subjects: 59
Study: 37553688

Group type: COMPARATOR
Intervention: Traditional symptom severity decision-making algorithm
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Novel multivariate decision-making algorithm
Number of subjects: 1000
Study: 37553699

Group type: EXPERIMENTAL
Intervention: Ad libitum clear liquids up to 2 hours prior to procedure
Number of subjects: 181

Group type: COMPARATOR
Intervention: Nil per os (NPO) after midnight (control group)
Number of subjects: 181
Study: 37553840

Group type: EXPERIMENTAL
Intervention: Community Support Intervention (CSI)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Education group
Number of subjects: 33
Study: 37553873

Group type: EXPERIMENTAL
Intervention: Bosutinib 500 mg QD
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Bosutinib 400 mg QD
Number of subjects: 573

Group type: COMPARATOR
Intervention: Imatinib
Number of subjects: 573
Study: 37553874

Group type: EXPERIMENTAL
Intervention: Berberine (BBR) hydrochloride
Number of subjects: 0
Study: 37554074

Group type: EXPERIMENTAL
Intervention: Household members screened for depressive disorder using PHQ-9
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Household members with elevated depression symptom severity
Number of subjects: 0
Study: 37554078

Group type: COMPARATOR
Intervention: Insulin-controlled euglycemia (control)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Total insulin withdrawal for 14 hours
Number of subjects: 9
Study: 37554123

Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance in TE patients
Number of subjects: 4358

Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance in TNE patients
Number of subjects: 4358

Group type: EXPERIMENTAL
Intervention: Double exposure to lenalidomide in TNE patients
Number of subjects: 4358
Study: 37554125

Group type: EXPERIMENTAL
Intervention: Sintilimab (200 mg, day 1) plus bevacizumab (7.5 mg/kg, day 1), oxaliplatin (135 mg/m2, day 1), and capecitabine as first-line therapy
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Sintilimab plus bevacizumab, oxaliplatin and capecitabine
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Exploratory biomarker assessment
Number of subjects: 25
Study: 37554174

Group type: EXPERIMENTAL
Intervention: Cell-based assay (CBA)
Number of subjects: 2272

Group type: EXPERIMENTAL
Intervention: Radioimmunoprecipitation assay (RIPA)
Number of subjects: 2272

Group type: EXPERIMENTAL
Intervention: Enzyme-linked immunosorbent assay (ELISA)
Number of subjects: 2272

Group type: COMPARATOR
Intervention: CBA
Number of subjects: 2272
Study: 37554284

Group type: EXPERIMENTAL
Intervention: Focused ultrasound
Number of subjects: 0
Study: 37554394

Group type: EXPERIMENTAL
Intervention: taVNS (transcutaneous auricular vagus nerve stimulation)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 30
Study: 37554510

Group type: EXPERIMENTAL
Intervention: Intravenous reinduction of Ustekinumab (UST) followed by subcutaneous q8w or q4w
Number of subjects: 128

Group type: COMPARATOR
Intervention: Shortening intervals of Ustekinumab (UST) q8w or q4w
Number of subjects: 128
Study: 37555165

Group type: EXPERIMENTAL
Intervention: Endovascular baroreflex amplification (EVBA) by implantation of the MobiusHD
Number of subjects: 13
Study: 37555197

Group type: COMPARATOR
Intervention: Heart attack education program delivered by trained HM Coordinators, supported by media and a geo-targeted social media campaign.
Number of subjects: 8
Study: 37555284

Group type: EXPERIMENTAL
Intervention: Entinostat 2 mg orally weekly in combination with standard dose carboplatin, etoposide, and atezolizumab
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Entinostat, atezolizumab, carboplatin, and etoposide
Number of subjects: 3
Study: 37555345

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) plus optimal medical and device therapy (OMT)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Optimal medical and device therapy (OMT) alone
Number of subjects: 700
Study: 37555595

Group type: EXPERIMENTAL
Intervention: Low-dose ato-oxy (0.5 mg/kg atomoxetine and 5 mg oxybutynin)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High-dose ato-oxy (1.2 mg/kg atomoxetine and 5 mg oxybutynin)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Health-related quality of life (OSA-18)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Changes in sleep architecture
Number of subjects: 15
Study: 37555738

Group type: EXPERIMENTAL
Intervention: Carboxymethylcellulose artificial tears
Number of subjects: 80

Group type: COMPARATOR
Intervention: Polyethylene glycol artificial tears
Number of subjects: 80
Study: 37555886

Group type: EXPERIMENTAL
Intervention: Absolute Change (AC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relative Change (RC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proposed Responder Endpoint
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher AC and RC thresholds
Number of subjects: 0
Study: 37555901

Group type: EXPERIMENTAL
Intervention: GRPR-targeted PET using mPROMISE criteria
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mPROMISE criteria
Number of subjects: 0
Study: 37555904

Group type: EXPERIMENTAL
Intervention: PD-1/L1 blockade
Number of subjects: 0
Study: 37556023

Group type: EXPERIMENTAL
Intervention: Lurbinectedin 3.2 mg/m²
Number of subjects: 0
Study: 37556078

Group type: EXPERIMENTAL
Intervention: RYHJ-GA (modified RYHJ with gastric access loop)
Number of subjects: 52

Group type: COMPARATOR
Intervention: RYHJ-C (conventional RYHJ)
Number of subjects: 52
Study: 37556123

Group type: EXPERIMENTAL
Intervention: Immediate coronary angiography
Number of subjects: 554

Group type: COMPARATOR
Intervention: Delayed or selective angiography
Number of subjects: 554
Study: 37556146

Group type: EXPERIMENTAL
Intervention: Baricitinib, 4 mg
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Baricitinib, 2 mg
Number of subjects: 1200
Study: 37556150

Group type: EXPERIMENTAL
Intervention: 12-week app-based exercise intervention (four 20-minute sessions per week using body weight interval training, yoga, barre, and running apps)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: 12-week app-based exercise intervention
Number of subjects: 288

Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 288
Study: 37556188

Group type: EXPERIMENTAL
Intervention: Strengths-based prevention education intervention for Black girls
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Focus group methodology and surveys
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Pretest of the intervention with the youth advisory board
Number of subjects: 200
Study: 37556515

Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg subcutaneously at week 0, week 4, and every 12 weeks thereafter
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg subcutaneously
Number of subjects: 55
Study: 37556734

Group type: EXPERIMENTAL
Intervention: ETP phenotype
Number of subjects: 1256

Group type: EXPERIMENTAL
Intervention: near-ETP phenotype
Number of subjects: 1256

Group type: EXPERIMENTAL
Intervention: non-ETP phenotype
Number of subjects: 1256

Group type: EXPERIMENTAL
Intervention: day-29 MRD ≥1% with end-consolidation MRD ≥0.01%
Number of subjects: 1256

Group type: COMPARATOR
Intervention: day-29 MRD <0.01% vs 0.01% to 0.1%
Number of subjects: 1256
Study: 37556775

Group type: EXPERIMENTAL
Intervention: Palbociclib
Number of subjects: 5698

Group type: EXPERIMENTAL
Intervention: Palbociclib + Endocrine Therapy (ET)
Number of subjects: 5698
Study: 37556856

Group type: EXPERIMENTAL
Intervention: Plyometric high-intensity interval training (PLYO), 8 weeks, twice weekly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cycle-oriented high-intensity interval training (CYC), 8 weeks, twice weekly
Number of subjects: 0
Study: 37556859

Group type: EXPERIMENTAL
Intervention: Loaded exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unloaded exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37556913

Group type: EXPERIMENTAL
Intervention: BI 894999 (Schedule A: 0.2, 0.5, 1.0, 1.5, 2.0, and 5.0 mg, Days 1-21/21-d cycle)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: BI 894999 (Schedule B: 1.5, 2.0, and 2.5 mg, Days 1-15/21-d cycle)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: BI 894999 (Schedule C: loading dose 5.0, 6.0, or 7.0 mg on Day 1 followed by maintenance dose 2.5, 3.0, or 3.5 mg, Days 2-7 and 15-21/28-d cycle)
Number of subjects: 77
Study: 37557957

Group type: EXPERIMENTAL
Intervention: Protein-enriched breakfast
Number of subjects: 12

Group type: COMPARATOR
Intervention: Carbohydrate-rich breakfast
Number of subjects: 12

Group type: COMPARATOR
Intervention: Extended morning fasting
Number of subjects: 12
Study: 37558060

Group type: EXPERIMENTAL
Intervention: Higher gestational vitamin D exposure
Number of subjects: 672
Study: 37558144

Group type: EXPERIMENTAL
Intervention: Heli-FX EndoAnchor System with Endurant stent graft
Number of subjects: 70
Study: 37558348

Group type: EXPERIMENTAL
Intervention: Pyrethroid (PY)-LLIN
Number of subjects: 39207

Group type: EXPERIMENTAL
Intervention: Pyriproxyfen PY-LLIN
Number of subjects: 39207

Group type: EXPERIMENTAL
Intervention: Piperonyl butoxide PY-LLIN
Number of subjects: 39207

Group type: EXPERIMENTAL
Intervention: Chlorfenapyr PY-LLIN
Number of subjects: 39207
Study: 37558369

Group type: EXPERIMENTAL
Intervention: Transapical beating-heart septal myectomy (TA-BSM)
Number of subjects: 47
Study: 37558371

Group type: EXPERIMENTAL
Intervention: S-ICD
Number of subjects: 101
Study: 37558400

Group type: EXPERIMENTAL
Intervention: Disease-modulating therapy (DMT)
Number of subjects: 1645

Group type: COMPARATOR
Intervention: Interferons
Number of subjects: 1645

Group type: COMPARATOR
Intervention: Teriflunomide
Number of subjects: 1645
Study: 37558445

Group type: EXPERIMENTAL
Intervention: AndroidAPS (Do-it-yourself artificial pancreas system)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sensor-augmented pump
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: AndroidAPS
Number of subjects: 24
Study: 37558604

Group type: EXPERIMENTAL
Intervention: Obstructive coronary artery disease (oCAD)
Number of subjects: 1836

Group type: EXPERIMENTAL
Intervention: Revascularization
Number of subjects: 1836

Group type: EXPERIMENTAL
Intervention: Coronary microvascular dysfunction (CMD)
Number of subjects: 1836

Group type: EXPERIMENTAL
Intervention: Normal invasive measurements
Number of subjects: 1836

Group type: EXPERIMENTAL
Intervention: Target vessel failure
Number of subjects: 1836
Study: 37558912

Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray (ESK) plus oral antidepressant (AD)
Number of subjects: 96

Group type: COMPARATOR
Intervention: AD plus placebo nasal spray (PBO)
Number of subjects: 96
Study: 37558990

Group type: EXPERIMENTAL
Intervention: Standard-of-Care + MGVA (multidisciplinary group videoconferencing approach)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard-of-Care alone
Number of subjects: 18
Study: 37559004

Group type: EXPERIMENTAL
Intervention: WEBAPPAC web-application support
Number of subjects: 438

Group type: COMPARATOR
Intervention: Standard management
Number of subjects: 438
Study: 37559023

Group type: EXPERIMENTAL
Intervention: Standard adequate haemodialysis with a dialysate potassium concentration of 2.0 mmol/L
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Standard adequate haemodialysis
Number of subjects: 600
Study: 37559026

Group type: EXPERIMENTAL
Intervention: Leptin levels
Number of subjects: 265
Study: 37559050

Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg per day for 21 days every 28 days
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 15
Study: 37559069

Group type: EXPERIMENTAL
Intervention: T1 (assigned subgoal)
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: T2 (participatory subgoal)
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: T3 (fixed goal)
Number of subjects: 628

Group type: COMPARATOR
Intervention: Control (usual standard of care)
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 628
Study: 37559112

Group type: EXPERIMENTAL
Intervention: Hypnosis (2 sessions, one per week, plus usual rehabilitation program)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Usual rehabilitation program only
Number of subjects: 32
Study: 37559142

Group type: EXPERIMENTAL
Intervention: Pyrotinib plus capecitabine
Number of subjects: 100
Study: 37559158

Group type: EXPERIMENTAL
Intervention: SMARThealth Pregnancy intervention (education program, app for screening, monitoring dashboard, supply chain monitoring, stakeholder engagement)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care with additional health worker education (control group)
Number of subjects: 30
Study: 37559163

Group type: EXPERIMENTAL
Intervention: Targeted temperature management (TTM) with serum NSE measured at 48 hours after return of spontaneous circulation.
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: NSE cutoff values for predicting poor outcome with FPR < 1% in non-shockable group.
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: NSE cutoff values for predicting poor outcome with FPR < 1% in shockable group.
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Prognostic performance of NSE assessed by area under the receiver operating characteristic curve.
Number of subjects: 623
Study: 37559343

Group type: EXPERIMENTAL
Intervention: Tripegfilgrastim
Number of subjects: 27

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 27
Study: 37559349

Group type: EXPERIMENTAL
Intervention: Total intra venous anesthesia (TIVA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: General anesthesia with volatile anesthetics (VOL)
Number of subjects: 0
Study: 37559435

Group type: EXPERIMENTAL
Intervention: Synthetic 7T images generated by a generative adversarial network (SynGAN) from 3T images.
Number of subjects: 122

Group type: COMPARATOR
Intervention: Acquired 7T images.
Number of subjects: 122
Study: 37559530

Group type: EXPERIMENTAL
Intervention: Caffeine therapy (n = 12)
Number of subjects: 28

Group type: COMPARATOR
Intervention: No caffeine therapy (n = 16)
Number of subjects: 28
Study: 37559718

Group type: EXPERIMENTAL
Intervention: Atezolizumab monotherapy
Number of subjects: 85

Group type: COMPARATOR
Intervention: Atezolizumab + Lenalidomide
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Atezolizumab + Daratumumab + Pomalidomide
Number of subjects: 85
Study: 37559753

Group type: EXPERIMENTAL
Intervention: 250 mg lufotrelvir (SAD)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 500 mg lufotrelvir (SAD)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (SAD)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 250 mg lufotrelvir (MAD)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 500 mg lufotrelvir (MAD)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (MAD)
Number of subjects: 30
Study: 37559752

Group type: EXPERIMENTAL
Intervention: Visceral Adiposity Index (VAI)
Number of subjects: 45
Study: 37559825

Group type: EXPERIMENTAL
Intervention: avalglucosidase alfa
Number of subjects: 100

Group type: COMPARATOR
Intervention: alglucosidase alfa
Number of subjects: 100
Study: 37560085

Group type: EXPERIMENTAL
Intervention: COVID-19 convalescent plasma (CCP) with high titer neutralizing activity
Number of subjects: 702

Group type: COMPARATOR
Intervention: 0.9% saline (placebo)
Number of subjects: 702
Study: 37560089

Group type: EXPERIMENTAL
Intervention: Empowerment-based intervention
Number of subjects: 0
Study: 37560161

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily (BID)
Number of subjects: 1139

Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 1139
Study: 37560175

Group type: EXPERIMENTAL
Intervention: eIPOS (electronic Integrated Palliative Care Outcome Scale)
Number of subjects: 0
Study: 37560259

Group type: EXPERIMENTAL
Intervention: Toripalimab combined with neoadjuvant chemoradiotherapy (NCRT)
Number of subjects: 44
Study: 37560461

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37560749

Group type: EXPERIMENTAL
Intervention: Base-producing fruit and vegetables (experimental group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sodium bicarbonate (control group)
Number of subjects: 40